JERSEY CITY, NJ--(Marketwire - January 05, 2010) -
QUMAS, the leading provider of Compliance
Solutions to highly regulated companies, today announced that Siena Biotech
SpA has selected the QUMAS Biotechnology Package (based on the industry
leading eDMS DocCompliance) to improve document control, reduce approval
lifecycles of documents and SOPs, and to become eCTD ready. Siena Biotech
SpA has also selected QUMAS ProcessCompliance to automate Change Control
and Non-Conformance Management and drive efficiencies across both
processes. Initially, Siena Biotech SpA will roll the QUMAS applications
out to 30 users.
"With this Package, Siena Biotech SpA is gaining access to a world class
document management solution, packaged to ensure low acquisition and
implementation costs for biotechnology companies," said Ken Hayward, CTO at
QUMAS. "By harnessing the power of DocCompliance with pre-configured
industry practices for R&D leading to eCTD readiness, Siena Biotech SpA
will be up and running with this solution very quickly."
Siena Biotech chose the QUMAS Solutions because of the built in best
practices for biotechnology operations, which suited its IT department that
did not have the bandwidth to spend months configuring systems. The QUMAS
Quickstart approach means that the organization will be up and running in a
short time frame, with a relatively low cost. According to Siena Biotech,
the look and feel of the interface is great, and very user-friendly.
Goran Westerberg, head of Development Operations in Siena Biotech SpA
commented: "We were in the market for a flexible and up-to-date system for
document management and found QUMAS Solutions to be the ideal fit for our
organization, allowing the system to grow with the portfolio of the
Company."
Federico Paoli, Siena Biotech's head of IT, concluded that "QUMAS was able
to quickly map our needs and provide a solution that fits our
infrastructure."
H@rlock, the QUMAS partner in Italy, has been instrumental in engaging
Siena Biotech with QUMAS, in providing local representation and continue to
represent QUMAS throughout the Italian market.
This announcement marks the beginning of a new area of business for QUMAS,
extending its traditional tier one and two life sciences focus further
across the sector to smaller organizations that require the same solutions,
but at a lower cost and in an easy to implement format.
About QUMAS: QUMAS is the leader in Enterprise Regulatory Compliance
Solutions with more than 250 global customer deployments and over 15 years
of experience helping companies in highly regulated industries. For more
information visit www.qumas.com
About Siena Biotech: Siena Biotech SpA is an innovative drug discovery
company focused primarily on degenerative and proliferative diseases of the
central nervous system with the aim of discovering new drugs for
therapeutic intervention.
The company was established in 2000 by the Monte dei Paschi di Siena (MPS)
Foundation, which is a non-profit, private institution. Since its
inception, the company has grown rapidly to achieve the critical mass
needed to compete successfully, and has developed a well-balanced and
innovative project portfolio focused on the CNS diseases of Alzheimer's and
Huntington's diseases and brain tumours. For more information visit
www.sienabiotech.com
